Tailoring small proteins towards biomedical applications

Curr Pharm Biotechnol. 2011 Nov;12(11):1792-8. doi: 10.2174/138920111798376905.

Abstract

Over the last two decades proteins have become increasingly important in human therapy and diagnosis. Engineering therapeutic proteins through improving their biological activity and stability has been a major interest in our group. In this mini-review we summarize our research on three proteins with pharmaceutical potential - serine protease inhibitor from squash seeds (CMTI), bovine pancreatic trypsin inhibitor (BPTI), and human fibroblast growth factor 1 (FGF1). To improve the functional properties of these proteins we used multiple techniques such as homology approach, rational design, total chemical synthesis, site-directed mutagenesis and phage display. The physicochemical properties of the obtained protein variants were evaluated using protein crystallography, spectroscopic techniques, enzymatic assays, stability measurements as well as numerous biological tests.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Aprotinin* / chemistry
  • Aprotinin* / genetics
  • Aprotinin* / pharmacology
  • Cattle
  • Cucurbita / chemistry
  • Drug Discovery / methods*
  • Fibroblast Growth Factor 1* / chemistry
  • Fibroblast Growth Factor 1* / genetics
  • Fibroblast Growth Factor 1* / pharmacology
  • Humans
  • Mutagenesis, Site-Directed
  • Protein Engineering / methods*
  • Protein Stability
  • Seeds / chemistry
  • Serine Proteinase Inhibitors* / chemistry
  • Serine Proteinase Inhibitors* / genetics
  • Serine Proteinase Inhibitors* / pharmacology

Substances

  • Serine Proteinase Inhibitors
  • Fibroblast Growth Factor 1
  • Aprotinin